Company Encyclopedia
View More
name
Carisma Therapeutics
CARM.US
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma.
1.932 T
CARM.USMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking49/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-134.11%E
    • Profit Margin15.28%A
    • Gross Margin99.56%A
  • Growth ScoreA
    • Revenue YoY159.68%A
    • Net Profit YoY112.61%A
    • Total Assets YoY-84.42%E
    • Net Assets YoY92.21%A
  • Cash ScoreB
    • Cash Flow Margin654.46%C
    • OCF YoY159.68%A
  • Operating ScoreA
    • Turnover2.17A
  • Debt ScoreE
    • Gearing Ratio113.23%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Carisma Therapeutics (OTCID: CARM) to voluntarily delist from Nasdaq, Board approved decision.

    Philadelphia-based company Carisma Therapeutics Inc. (OTCID: CARM) revealed plans to voluntarily delist its common stock from The Nasdaq Stock Market LLC. The decision was approved by the Board of Directors and marks a significant move for the Company. The delisting process signifies a strategic shift, and shareholders will need to consider their next steps as a result.

    Unusual Whales·
    US
    CARM
    +2.72%
    Unusual Whales·
    US
    CARM
    +2.72%

    Carisma Announces Delisting from Nasdaq and SEC Deregistration | CARM Stock News

    Carisma Therapeutics Inc. announced its voluntary delisting from Nasdaq and deregistration with the SEC to terminate its reporting obligations. This decision follows a delist determination due to noncompliance with Nasdaq's listing rules. The company's stock will trade on the OTCID market. The delisting is expected to be effective by December 25, 2025, with deregistration effective 90 days post-Form 15 filing. Carisma aims to preserve cash for an orderly wind-down of operations.

    StockTitan·
    US
    CARM
    +2.72%
    StockTitan·
    US
    CARM
    +2.72%

    Carisma Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 45.25 M

    LB filings·
    US
    CARM
    +2.72%
    LB filings·
    US
    CARM
    +2.72%

    Carisma Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

    Carisma Therapeutics Inc is anticipated to report a loss of 12 cents per share for the quarter ending September 30, 2025, with results expected on November 5. Analysts maintain a "buy" rating, with one strong buy, one hold, and no sell recommendations. The median 12-month price target is $1.00, representing a potential increase of 94.4% from the last closing price of $0.06.

    Reuters·
    US
    CARM
    +2.72%
    Reuters·
    US
    CARM
    +2.72%

    Carisma Therapeutics - CEO Steven Kelly To Leave Effective Nov 15 - SEC Filing

    Oct 15 (Reuters) - Carisma Therapeutics Inc (CARM.PK) :* AS PART OF WIND DOWN ACTIVITIES, CEO STEVEN KELLY TO LEAVE EFFECTIVE NOV 15 - SEC FILING* TO APPOINT CONSULTANT TO SERVE AS CEO & MANAGE REMAINING WIND-DOWN ACTIVITIES Source text: Further company coverage: (CARM.PK)

    Reuters·
    US
    CARM
    +2.72%
    Reuters·
    US
    CARM
    +2.72%
    © 2025 Longbridge｜Disclaimer